Business Context and Reporting Period
This Form 8-K filing by GlycoMimetics, Inc. (not Crescent Biopharma, Inc.) reports a material definitive agreement entered into on March 24, 2016. The filing concerns a First Amendment to a Lease Agreement with BMR-Medical Center Drive LLC regarding the company's principal executive offices in Rockville, Maryland.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details specific lease financial terms:
- Additional Space: 12,074 square feet at 9712 Medical Center Drive.
- Annual Base Rent: $313,924 ($26,160.33 per month), subject to a 2.5% annual increase.
- Additional Costs: Pro rata share of operating expenses and a 3% property management fee on base rent.
- Security Deposit: $52,320.
- Landlord Improvements: $603,700 in tenant improvements provided by the landlord.
Material Changes
The primary material change is the expansion of the company's leased footprint. The amendment modifies the original July 23, 2014, Lease Agreement to include the additional 12,074 square feet. The lease term for the new space runs through October 31, 2023, aligning with the original lease expiration, and includes the same termination option effective October 31, 2020.
Outlook and Risks
The filing does not provide forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the contractual obligations of the lease. The commencement of rent payments for the additional space is contingent on the earlier of June 1, 2016, the substantial completion of work, or the commencement of operations on the premises.
Investor Verification Checklist
- Verify the company name discrepancy: The filing is for GlycoMimetics, Inc., not Crescent Biopharma, Inc.
- Confirm the exact date rent obligations begin for the additional 12,074 square feet.
- Review the full text of Exhibit 10.1 for detailed clauses regarding operating expense calculations and termination rights.
- Assess the impact of the $603,700 in landlord improvements on the company's future capital expenditure plans.